Effect of Academic Detailing on Promoting Appropriate Prescribing of Antipsychotic Medication in Nursing Homes: A Cluster Randomized Clinical Trial.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 05 2020
01 05 2020
Historique:
entrez:
27
5
2020
pubmed:
27
5
2020
medline:
27
10
2020
Statut:
epublish
Résumé
Strategies to reduce the inappropriate prescription of antipsychotics have been the focus of recent attention but have shown considerable variation in their effectiveness. To evaluate the effectiveness of academic detailing in nursing homes targeting appropriate prescribing of antipsychotics. We conducted a pragmatic, cluster randomized clinical trial comparing the effect of academic detailing vs usual care on prescribing antipsychotics in 40 nursing homes with 5363 residents in Ontario, Canada. Data were collected from October 2015 to March 2016 and analyzed from April to August 2018. Primary analyses were conducted using intention to treat. Academic detailing delivered by health professionals (eg, nurses or pharmacists) who arranged meetings (with administrators, physicians, pharmacists, nurses, and support workers), presentations, group visits (with 2-6 clinicians), and 1-on-1 visits (traditional academic detailing visits). Academic detailers had direct and ongoing contact with the nursing homes from the time of launch. The primary outcome, defined at the level of the resident, was whether continuous antipsychotics were dispensed in the past week. Secondary outcomes included prescribing of other psychotropic medications and clinical outcomes and scores. Prescribing outcomes were assessed at baseline and at 3, 6, and 12 months, and clinical outcomes and scores were assessed at baseline and 3 and 6 months. A total of 40 nursing homes with 5363 residents were randomized, with 18 intervention homes (45.0%; 2303 [42.9%] residents) and 22 control homes (55.0%; 3060 [57.1%] residents). Participants in the intervention and control groups had similar median (interquartile range) age (86 [79-91] years vs 85 [78-90] years) and sex (674 [29.3%] men vs 970 [31.7%] men). At 12 months, there was no statistically significant difference in the frequency of daily antipsychotic use (intervention: 569 patients [25.2%]; control: 769 [25.6%]; odds ratio, 1.06; 95% CI, 0.93-1.20; P = .49). There were no significant differences in the rates of health care utilization, but the intervention group did experience a statistically significant reduction in pain compared with the control group (mean [SD] pain score, 0.30 [0.59] vs 0.38 [0.66]; P < .001) and depression (mean [SD] Depression Rating Scale score, 2.18 [2.37] vs 2.81 [2.65]; P < .001) at 6 months. The intervention did not further reduce antipsychotic prescribing in nursing homes beyond system-level secular trends occurring alongside usual care. Our findings highlight the need for a more targeted approach to quality improvement strategies, including academic detailing, that account for the timing and topic of interventions. ClinicalTrials.gov Identifier: NCT02604056.
Identifiants
pubmed: 32453383
pii: 2766202
doi: 10.1001/jamanetworkopen.2020.5724
pmc: PMC7251442
doi:
Substances chimiques
Antipsychotic Agents
0
Banques de données
ClinicalTrials.gov
['NCT02604056']
Types de publication
Journal Article
Pragmatic Clinical Trial
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e205724Références
Cochrane Database Syst Rev. 2007 Oct 17;(4):CD000409
pubmed: 17943742
Implement Sci. 2017 May 26;12(1):71
pubmed: 28549480
J Contin Educ Health Prof. 2019 Winter;39(1):21-28
pubmed: 30789377
Int J Geriatr Psychiatry. 2009 Oct;24(10):1110-8
pubmed: 19280680
BMJ. 2004 Jun 12;328(7453):1415-6
pubmed: 15138157
Implement Sci. 2016 Mar 29;11:45
pubmed: 27026584
J Gerontol A Biol Sci Med Sci. 1999 Nov;54(11):M546-53
pubmed: 10619316
J Am Geriatr Soc. 2015 Feb;63(2):302-8
pubmed: 25643635
BMC Geriatr. 2005 Jan 01;5:1
pubmed: 15627403
BMJ Qual Saf. 2019 Feb;28(2):121-131
pubmed: 30061102
Age Ageing. 2000 Mar;29(2):165-72
pubmed: 10791452
BMJ. 2015 May 08;350:h2147
pubmed: 25956159
Drugs Aging. 2016 Jul;33(7):523-33
pubmed: 27241038
BMC Health Serv Res. 2003 Nov 04;3(1):20
pubmed: 14596684
J Am Geriatr Soc. 2003 Sep;51(9):1305-17
pubmed: 12919245
CMAJ. 2009 Mar 31;180(7):713-8
pubmed: 19176635
JAMA. 2005 Oct 19;294(15):1934-43
pubmed: 16234500
Arch Intern Med. 2007 Apr 9;167(7):676-83
pubmed: 17420426
J Am Med Dir Assoc. 2014 Oct;15(10):706-18
pubmed: 25112229
J Clin Psychopharmacol. 2014 Feb;34(1):109-23
pubmed: 24158020
Health Policy. 2014 Sep;117(3):392-8
pubmed: 25082467
Arch Intern Med. 2008 May 26;168(10):1090-6
pubmed: 18504337
BMJ. 2012 Sep 04;345:e5661
pubmed: 22951546
Br J Clin Pharmacol. 2017 Jul;83(7):1521-1531
pubmed: 28071806
N Engl J Med. 1983 Jun 16;308(24):1457-63
pubmed: 6406886
J Alzheimers Dis. 2014;42(3):915-37
pubmed: 25024323
N Engl J Med. 2009 Jan 15;360(3):225-35
pubmed: 19144938
BMC Health Serv Res. 2008 Dec 30;8:277
pubmed: 19115991
Gerontologist. 2001 Apr;41(2):173-9
pubmed: 11327482
Cochrane Database Syst Rev. 2012 Jun 13;(6):CD000259
pubmed: 22696318
JAMA. 1990 Jan 26;263(4):549-56
pubmed: 2104640
Can Geriatr J. 2018 Sep 30;21(3):269-273
pubmed: 30271512
BMJ. 2008 Nov 11;337:a2390
pubmed: 19001484
Ann Pharmacother. 2015 Jan;49(1):20-8
pubmed: 25380592